|
Real-time Estimate
Cboe BZX
17:38:37 19/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.285 USD | +6.59% |
|
+1.67% | -63.52% |
| 08-13 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-13 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
| Market Cap | 400M 355M 329M 300M 565M 37.94B 575M 3.96B 1.55B 19.8B 1.5B 1.47B 63.12B | P/E 2026 * |
-2.16x | P/E 2027 * | -4.76x |
|---|---|---|---|---|---|
| Enterprise Value | 400M 355M 329M 300M 565M 37.94B 575M 3.96B 1.55B 19.8B 1.5B 1.47B 63.12B | EV / Sales 2026 * |
3.11x | EV / Sales 2027 * | 2.14x |
| Free-Float |
83.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SPRY | Delayed | |
CBOE
| SPRY | Real-time |
Last Transcript: ARS Pharmaceuticals, Inc.
| 1 day | +5.35% | ||
| 1 week | +1.67% | ||
| Current month | -1.39% | ||
| 1 month | -2.30% | ||
| 3 months | -34.01% | ||
| 6 months | -48.04% | ||
| Current year | -63.52% |
| 1 week | 3.81 |  | 4.29 |
| 1 month | 3.81 | | 4.64 |
| Current year | 3.81 | | 13.15 |
| 1 year | 3.81 | | 13.15 |
| 3 years | 3.35 | | 18.9 |
| 5 years | 2.55 | | 18.9 |
| 10 years | 2.55 | | 18.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bell
CTO | Chief Tech/Sci/R&D Officer | - | 04/08/2015 |
Donn Casale
CEO | Chief Executive Officer | 53 | 06/07/2026 |
Kathleen Scott
DFI | Director of Finance/CFO | 57 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CHM | Chairman | 56 | 07/11/2022 |
Rajeev Dadoo
BRD | Director/Board Member | 55 | 31/07/2021 |
Saqib Islam
BRD | Director/Board Member | 56 | 30/06/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Free | Chief Executive Officer | 1,036,923 | 1.0427% | ||
| 01/09/26 | Free | Executive/Senior Manager | 1,001,738 | 1.0073% | ||
| 01/07/26 | Free | Chief Executive Officer | 898,456 | 0.9048% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.47% | +1.67% | -57.54% | +25.74% | 400M | |
| +1.52% | -7.16% | +51.66% | +67.41% | 65B | |
| +1.52% | +6.83% | +10.89% | +79.30% | 51.2B | |
| +0.30% | -0.46% | -0.03% | +61.89% | 51.19B | |
| -0.80% | +0.87% | +24.73% | +41.63% | 43.93B | |
| +0.39% | +5.72% | +16.27% | +133.46% | 41.96B | |
| +2.25% | -6.51% | +235.73% | +525.28% | 38.14B | |
| +2.16% | +10.36% | +18.92% | +59.70% | 33.24B | |
| -0.90% | -10.49% | +37.09% | +1.80% | 25.2B | |
| +1.60% | +2.21% | +27.96% | +28.00% | 22.5B | |
| Average | +1.28% | -0.37% | +36.57% | +102.42% | 37.28B | |
| Weighted average by Cap. | +0.86% | +0.03% | +45.19% | +111.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 129M 114M 106M 96.38M 182M 12.2B 185M 1.27B 499M 6.37B 483M 472M 20.3B | 187M 166M 154M 140M 265M 17.76B 269M 1.85B 727M 9.27B 702M 687M 29.54B |
| Net income | -185M -164M -152M -139M -262M -17.55B -266M -1.83B -718M -9.16B -694M -679M -29.19B | -85.17M -75.71M -70.17M -63.84M -120M -8.08B -122M -843M -331M -4.22B -320M -313M -13.45B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/10/26 | US$4.250 | +5.72% | 686,865 |
| 16/10/26 | US$4.020 | -1.23% | 2,332,021 |
| 15/10/26 | US$4.070 | +3.56% | 2,220,134 |
| 14/10/26 | US$3.930 | -2.96% | 1,729,601 |
| 13/10/26 | US$4.050 | -3.11% | 1,546,825 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SPRY Stock
Select your edition
All financial news and data tailored to specific country editions
